Amyris makes progress on RNA COVID-19 vaccine platform

February 22, 2021 |

In California, Amyris announced highly promising preliminary data in a pre-clinical study of its ribonucleic acid (RNA) COVID-19 vaccine platform as well as the potential to address current manufacturing, supply scale-up and refrigerated storage and distribution challenges.

On October 22, 2020, Amyris announced that it entered into a collaboration agreement and exclusive license with the Infectious Disease Research Institute (IDRI) to advance a novel RNA vaccine platform, including the development of a COVID-19 vaccine.

Preliminary data from a pre-clinical study of IDRI’s Nanostructured Lipid Carrier (NLC) vaccine platform demonstrated a significant level of antibody production against the COVID-19 spike protein using a self-adjuvanting RNA vaccine. The results were consistent with similar data published by Moderna and Pfizer/BioNTech on their respective messenger RNA technologies. The Amyris/IDRI platform will be advancing to phase 1 clinical trials with the support of the Portuguese government and other partnerships.

The Amyris/IDRI RNA platform technology is expected to offer manufacturing, storage, and distribution advantages for the use and development of future vaccines, and to address the ongoing evolution of SARS-CoV-2 (COVID-19) and other potential pandemics.

Print Friendly, PDF & Email

Tags: , ,

Category: Research

Thank you for visting the Digest.